Automate injectable drug delivery with the customizable OmniPod by Insulet. See how it's improving lives with better adherence and seamless delivery.
836 2% Last mo
Use Insulet's historical employee count to better understand their growth and spending over time.
Unlock with a Free Trial
Use Insulet's historical monthly uniques as a proxy for mindshare and web traction.
Use Insulet's historical Twitter followers and likes to better understand their social media traction over time.
Use Insulet's historical Linkedin followers to better understand their social media traction over time.
Use Insulet's mobile downloads and app ranks to evaluate the performance of their mobile apps.
Raymond James Increases Insulet (NASDAQ:PODD) Rating to Outperform from Mkt Perform
Free Research Report as Insulet’s Revenue Grew 28.4%
Insulet Announces Pricing of Convertible Senior Notes Due 2024
Insulet Announces Private Offering of Convertible Senior Notes
Insulet (NASDAQ:PODD) Rating was Improved by Professional Analysts at Canaccord from “Hold” to “Buy”. The Target Price per Share is to $65.0